Top 15+ Cc-5013-nhl-007 hay nhất
-
1.Rituximab Plus Lenalidomide For Patients With Relapsed ...
This double-blind randomized, parallel group study will evaluate the efficacy and safety of lenalidomide (Revlimid, CC-5013) in combination with rituximab ...
Xem chi tiết » -
2.[PDF] CELGENE PROPRIETARY INFORMATION
CC 5013 NHL 007. A PHASE 3, DOUBLE BLIND RANDOMIZED STUDY TO COMPARE THE. EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC 5013).
Xem chi tiết » -
3.EU Clinical Trials Register
7 Nov 2013 · Sponsor's Protocol Code Number: CC-5013-NHL-007. National Competent Authority: Portugal - INFARMED. Clinical Trial Type: EEA CTA.
Xem chi tiết » -
4.A Phase III Study Of Lenalidomide Plus Rituximab Versus Placebo ...
10 May 2019 · Lenalidomide improved efficacy of rituximab in patients with recurrent indolent lymphoma, with an acceptable safety profile.
Xem chi tiết » -
5.Celgene-cc-5013-nhl-007 By Gibbs - Issuu
Lymphoma, Non-Hodgkin This double-blind randomized, parallel group study will evaluate the efficacy and safety of lenalidomide (Revlimid, CC-5013) in ...
Xem chi tiết » -
6.Clinical Trials - Mayo Foundation For Medical Education And Research
This double-blind randomized, parallel group study will evaluate the efficacy and safety of lenalidomide (Revlimid, CC-5013) in combination with rituximab ...
Xem chi tiết » -
7.Revlimid 5 Mg Hard Capsules - Summary Of Product Characteristics ...
In patients with high tumour burden, corresponding figures were 16/81 (20%) and 2/28 (7%) (see section 4.4). Follicular lymphoma. AUGMENT - CC-5013-NHL-007. The ...
Xem chi tiết » -
8.[PDF] Lenalidomide-accord-epar-product-information_en.pdf
AUGMENT - CC-5013-NHL-007. The efficacy and safety of lenalidomide in combination with rituximab versus rituximab plus placebo.
Xem chi tiết » -
9.Lenalidomide - Celgene Corporation - AdisInsight - Springer
5 Jul 2022 · ... relapsed or refractory indolent non-Hodgkin's lymphoma (follicular lymphoma or marginal zone lymphoma) (CC-5013-NHL-007; NCT01938001).
Xem chi tiết » -
10.ICTRP Search Portal
25 Jan 2016 · ... Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma.
Xem chi tiết » -
11.[PDF] Revlimid, INN-lenalidomide - European Medicines Agency
14 Nov 2019 · In Pivotal study AUGMENT (CC-5013-NHL-007) the starting dose of lenalidomide is 20 mg administered daily for 21 consecutive days in each ...
Xem chi tiết » -
12.Lenalidomide Lymphoma MAGNIFY (CC-5013-NHL-008)
Lenalidomide Lymphoma MAGNIFY (CC-5013-NHL-008). Review clinical trials at Sutter Health. Missing: 007 | Must include: 007
Xem chi tiết » -
13.[PDF] EU-RISK MANAGEMENT PLAN FOR REVLIMID (LENALIDOMIDE)
20 Dec 2019 · CC-5013-NHL-007: Phase 3, double-blind, randomised study to compare the efficacy and safety of rituximab plus lenalidomide versus rituximab ...
Xem chi tiết » -
14.Lymphoma & Myeloma Clinical Trials | MD Anderson Cancer Center
18 May 2022 · ... with Relapsed or Refractory Indolent B-Cell Non-Hdgkin Lymphoma (NHL) ... Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM).
Xem chi tiết » -
15.[PDF] SMC2281 - Scottish Medicines Consortium
12 Oct 2020 · lenalidomide (Revlimid®) is accepted for use within NHSScotland. ... Celgene Ltd. Clinical study report for CC-5013-NHL-007 (AUGMENT), ...
Xem chi tiết »